WO2000044711A1 - ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS - Google Patents
ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS Download PDFInfo
- Publication number
- WO2000044711A1 WO2000044711A1 PCT/US2000/001865 US0001865W WO0044711A1 WO 2000044711 A1 WO2000044711 A1 WO 2000044711A1 US 0001865 W US0001865 W US 0001865W WO 0044711 A1 WO0044711 A1 WO 0044711A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- carbon atoms
- heteroatoms selected
- amino
- sulfonyl
- Prior art date
Links
- 0 CC#CC(*)(*)***N(*)C(*)C(*)C(*)=O Chemical compound CC#CC(*)(*)***N(*)C(*)C(*)C(*)=O 0.000 description 6
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/78—Halides of sulfonic acids
- C07C309/86—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/87—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/41—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
- C07C309/42—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- This invention relates to acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acids which act as inhibitors of TNF- ⁇ converting enzyme
- TNF- ⁇ converting enzyme catalyzes the formation of TNF- ⁇ from membrane bound TNF- ⁇ precursor protein.
- TNF- ⁇ is a pro-inflammatory cytokine that is believed to have a role in rheumatoid arthritis [Shire, M. G.; Muller, G. W. Exp. Opin. Ther. Patents 1998, 8(5), 531; Grossman, J. M.; Brahn, E. J. Women's Health 1997, 6(6), 627; Isomaki, P.; Punnonen, J. Ann. Med. 1997, 29, 499; Camussi, G.; Lupia, E. Drugs, 1998, 55(5), 613.] septic shock [Mathison, et. al.
- sulfonamide hydroxamic acid MMP/TACE inhibitors in which a 2 carbon chain separates the hydroxamic acid and the sulfonamide nitrogen, as shown below, are disclosed in WIPO international publications WO9816503, WO9816506, WO9816514 and WO9816520 and U. S. patent 5,776,961.
- Sulfonamide MMP/TACE inhibitors in which a thiol is the zinc chelating group, as shown below, have been disclosed in WIPO international application 9803166.
- Y the sulfonyl or phosphinyl aryl
- These compounds provide enhanced levels of inhibition of the activity of TACE in vitro and in a cellular assay and/or selectivty over MMP-1. These compounds may therefore be used in the treatment of diseases mediated by TNF.
- TACE and MMP inhibiting ortho-sulfonamido hydroxamic acids of the present invention are represented by the formula:
- Z is O, NH, CI ⁇ or S;
- R 5 is hydrogen or alkyl of 1-6 carbon atoms;
- R ⁇ and R 12 are, independently, hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, a 5-7 membered heteroaryl having 1-3 heteroatoms selected from N, NR 9 , S and O, a 5-7 membered heterocycloalkyl having 1 or 2 heteroatoms selected from N, NR,, S and O, or phenyl, and the optional double bond represented by the dotted line is present; or
- Preferred compounds of this invention include compounds of structure B wherein X is SO 2 .
- More preferred compounds of this invention include compounds of structure B wherein X is SO 2 and Y is a phenyl ring substituted at the 1- and 4-positions by X and Z, respectively.
- More preferred compounds of this invention include compounds of structure B wherein X is SO 2 N is a phenyl ring substituted at the 1- and 4-positions by X and Z, respectively, and Z is oxygen.
- More preferred compounds of this invention include compounds of structure B wherein X is SO 2 N is a phenyl ring substituted at the 1- and 4-positions by X and Z, respectively, Z is oxygen and R 6 and R, are hydrogen.
- More preferred compounds of this invention include compounds of structure B wherein X is SO 2 N is a phenyl ring substituted at the 1- and 4-positions by X and Z, respectively, Z is oxygen, R 6 andR, are hydrogen and R g is -CH 2 OH or methyl.
- Heteroaryl as used throughout, is a 5-10 membered mono- or bicyclic ring having from 1-3 heteroatoms selected from N, NR 9 , S and O. Heteroaryl is preferably
- Halogen means bromine, chlorine, fluorine, and iodine.
- Suitable substituents of aryl, heteroaryl, alkyl, alkenyl, alkynyl, and cycloalkyl include, but are not limited to halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cyclocalkyl of 3-6 carbon atoms, -OR ; ,, -CN, -CO-R-,, perfluoroalkyl of 1-4 carbon atoms, -O-perfluoroalkyl of 1-4 carbon atoms, -CONR..R 3 ,
- Suitable substituents of heterocycloalkyl groups of the present invention include, but are not limited to alkyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, phenyl, naphthyl, heteroaryl and heterocycloalkyl.
- salts can be formed from organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, naphthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable acids when a compound of this invention contains a basic moiety.
- Salts may also be formed from organic and inorganic bases, preferably alkali metal salts, for example, sodium, lithium, or potassium, when a compound of this invention contains an acidic moiety.
- the compounds of this invention are shown to inhibit the enzymes MMP-1, MMP-9, MMP- 13 and TNF- ⁇ converting enzyme (TACE) and are therefore useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, graft rejection, insulin resistance, bone disease and HIV infection.
- TACE TNF- ⁇ converting enzyme
- the compounds of the invention provide enhanced levels of inhibition of the activity of TACE in vitro and in cellular assay and/or enhanced selectivity over MMP-1 and are thus particularly useful in the treatment of diseases mediated by TNF.
- this invention provides a process for preparing compounds of formula 1 , as defined above, which comprises one of the following: a) reacting a compound of formula V:
- Removal of protecting groups as illustrated by process b) can be carried out by processes known in the art to provide the hydroxamic acid.
- a racemic mixture may be converted to a mixture of optically active diastereoisomers by reaction with a single enantiomer of a 'resolving agent' (for example by diastereomeric salt formation or formation of a covalent bond).
- the resulting mixture of optically active diastereoisomers may be separated by standard techniques (e.g. crystallisation or chromatography) and individual optically active diastereoisomers then treated to remove the 'resolving agent' thereby releasing the single enantiomer of the compound of the invention.
- Chiral chromatography using a chiral support, eluent or ion pairing agent
- the compounds of formula B may be isolated in the form of a salt of a pharmaceutically acceptable acid e.g. an organic or inorganic acid by treatment with an acid such as described above.
- a pharmaceutically acceptable acid e.g. an organic or inorganic acid by treatment with an acid such as described above.
- the resultant sulfonyl chloride, fluoride or bromide may be further converted into triazolide, imidazolide or benzothiazolide derivatives, where J is 1,2,4-triazolyl, imidazol-yl or benzotriazolyl, by reacting the compound with 1,2,4-triazole, imidazole or benzotriazole, respectively.
- R 6 , R. and R g are as defined above.
- Compounds 3, wherein R ⁇ is a t-butyl, benzyl, trialkylsilyl or other suitable masking group may then be deprotected by known methods to provide the hydroxamic acid 1.
- the acetylenic side chain may also be appended after sulfonylation or phosphorylation of the amino acid derivative, as shown in Scheme 5.
- the amino acid derivatives 4 and 8 can be sulfonylated or phosphorylated with compounds 20, where ZR 50 is hydroxy or protected hydroxy, thiol or amine, and, if necessary, alkylated with R,J as in Scheme 2, to give 21. Removal of the R 50 masking group to give 22 and subsequent alkylation of the resulting phenol, thiol or amine with 10 provides 7. In the case where ZR 50 is equal to OH, no deprotection step is required to give 22.
- the propargylic amine analogs of 7 can be synthesized as shown in Scheme 6 starting from the amino acid derivatives 4 and/or 8.
- Sulfonylation or phosphorylation with para-nitro aryl compound 23, for example 4-nitrobenzenesulfonyl chloride, followed by alkylation with R 5 J (for 4) using a base such as potassium carbonate or sodium hydride in DMF provides 24.
- Reduction of the nitro moiety with hydrogen and palladium on carbon, tin chloride or other known method to give aniline 25 and subsequent alkylation with 10 then provides 7.
- Aniline 25 may be derivatized with a suitable nitrogen protecting group, such as t-butoxycarbonyl, to give 26 prior to alkylation with 10 subsequent deprotection after the alkylation step.
- Scheme 6 :
- Acetylenic derivatives 7 are also accessible via the fluoro compounds 27, readily prepared from the amino acid derivatives 4 and/or 8 by reaction with fluoraryl 26, as shown in Scheme 7.
- the fluorine of 27 can also be displaced in a polar aprotic solvent with the propargylic derivative 29, where Z is O, S or NH, in the presence of a base such as sodium hydride, to give 7 directly.
- Scheme 7 :
- Example 8 (cis)-2-[Benzyl-(4-methoxy-benzenesuIfonyI)-amino]-cyclohexanecarboxyIic acid
- 0.240 g (0.522 mmol) of the product from Example 6 provided 0.207 g (98%) of the desired carboxylic acid as a white solid.
- Example 25 to give a white solid (0.825 g), mp 172-175°C. Analysis for
- the thiopeptide substrate is made up fresh as a 20 mM stock in 100% DMSO and the DTNB is dissolved in 100% DMSO as a 100 mM stock and stored in the dark at room temperature. Both the substrate and DTNB are diluted together to 1 mM with substrate buffer (50 mM HEPES pH 7.5, 5 mM CaCl2) before use. The stock of enzyme is diluted with buffer (50 mM HEPES, pH 7.5, 5 mM CaCl2, 0.02% Brij) to the desired final concentration.
- substrate buffer 50 mM HEPES pH 7.5, 5 mM CaCl2
- buffer 50 mM HEPES, pH 7.5, 5 mM CaCl2, 0.02% Brij
- a fluorescent peptide substrate is used.
- the peptide substrate contains a fluorescent group and a quenching group.
- the fluorescence that is generated is quantitated on the fluorescence plate reader.
- the assay is run in HCBC assay buffer (50mM
- HEPES pH 7.0, 5 mM Ca+ 2 , 0.02% Brij, 0.5% Cysteine
- the substrate is dissolved in methanol and stored frozen in 1 mM aliquots.
- substrate and enzymes are diluted in HCBC buffer to the desired concentrations.
- Compounds are added to the 96 well plate containing enzyme and the reaction is started by the addition of substrate.
- the reaction is read (excitation 340 nm, emission 444 nm) for 10 min. and the increase in fluorescence over time is plotted as a linear line.
- Compounds can be evaluated for their effect on basal (non-stimulated) shedding of the receptors by replacing the LPS with 50 ml/well of THP-1 media. Plates are placed into an incubator set at 5% CO2 and at 37° C. After 4 hours of incubation, 300 ml/well of tissue culture supernatant (TCS) is removed for use in an TNF- ⁇ ELISA. Following 24 hours of incubation, 700 ml/well of TCS is removed and used for analysis in TNF-R p75/80, TNF-R p55/60 and IL-8 ELISAs.
- TCS tissue culture supernatant
- the cells for each treatment group are collected by resuspension in 500 ⁇ l/well of THP-1 media and transferred into a FACS tube.
- Two ml/tube of a 0.5 mg/ml stock of propidium iodide (PI) (Boerhinger Mannheim cat. # 1348639) is added.
- the samples are run on a Becton Dickinson FaxCaliber FLOW cytometry machine and the amount of dye taken up by each cell is measured in the high red wavelength (FL3). Only cells with compromised membranes (dead or dying) can take up PI.
- the percent of live cells is calculated by the number of cells not stained with PI, divided by the total number of cells in the sample.
- IC 50 values for each compound are calculated by non-linear regression analysis using customized software utilizing the JUMP statistical package.
- Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs.
- the active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
- a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
- the liquid carrier can contain other suitable pharmaceutical additives such a solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ512025A NZ512025A (en) | 1999-01-27 | 2000-01-27 | Acetylenic beta-sulphonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
BR0007754-2A BR0007754A (pt) | 1999-01-27 | 2000-01-27 | ácido de hidroxamida, processo para preparar osmesmos, composto, método de inibir mudançaspatológicas mediadas pela enzima que converte atnf-alfa (tage) em mamìfero em necessidade deste,e, composição farmacêutica |
IL14432100A IL144321A0 (en) | 1999-01-27 | 2000-01-27 | ACETYLENIC β-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID AS TACE INHIBITORS |
EA200100808A EA200100808A1 (ru) | 1999-01-27 | 2000-01-27 | ГИДРОКСАМОВЫЕ КИСЛОТЫ НА ОСНОВЕ АЦЕТИЛЕНОВОГО b-СУЛЬФОНАМИДО И АМИДА ФОСФИНОВОЙ КИСЛОТЫ, КАК ИНГИБИТОРЫ TACE |
JP2000595968A JP2002535383A (ja) | 1999-01-27 | 2000-01-27 | アセチレンβ−スルホンアミドおよびホスフィン酸アミドヒドロキサム酸TACE阻害剤 |
AU26306/00A AU769410B2 (en) | 1999-01-27 | 2000-01-27 | Acetylenic beta-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors |
KR1020017009153A KR20010089617A (ko) | 1999-01-27 | 2000-01-27 | 아세틸렌계 베타-설폰아미도 및 포스핀산 아미드하이드록삼산 티에이씨이 억제제 |
CA002356345A CA2356345A1 (en) | 1999-01-27 | 2000-01-27 | Acetylenic beta-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors |
EP00904570A EP1147078A1 (en) | 1999-01-27 | 2000-01-27 | Acetylenic (beta)-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors |
NO20013639A NO20013639D0 (no) | 1999-01-27 | 2001-07-24 | Acetyleniske <beta>-sulfonamido- og -fosfinsyreamid- hydroksamsyre-TACE-inhibitorer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23908399A | 1999-01-27 | 1999-01-27 | |
US09/239,083 | 1999-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000044711A1 true WO2000044711A1 (en) | 2000-08-03 |
Family
ID=22900530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/001865 WO2000044711A1 (en) | 1999-01-27 | 2000-01-27 | ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1147078A1 (ja) |
JP (1) | JP2002535383A (ja) |
KR (1) | KR20010089617A (ja) |
CN (1) | CN1337944A (ja) |
AR (1) | AR035478A1 (ja) |
AU (1) | AU769410B2 (ja) |
BR (1) | BR0007754A (ja) |
CA (1) | CA2356345A1 (ja) |
CZ (1) | CZ20012709A3 (ja) |
EA (1) | EA200100808A1 (ja) |
HU (1) | HUP0200605A3 (ja) |
IL (1) | IL144321A0 (ja) |
NO (1) | NO20013639D0 (ja) |
NZ (1) | NZ512025A (ja) |
WO (1) | WO2000044711A1 (ja) |
ZA (1) | ZA200104508B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005092844A1 (en) * | 2004-03-22 | 2005-10-06 | Southern Research Institute | Nonpeptide inhibitors of matrix metalloproteinases |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
US8633196B2 (en) | 2009-06-30 | 2014-01-21 | Galderma Research & Development | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
US9115102B2 (en) | 2009-09-17 | 2015-08-25 | Galderma Research & Development | N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514716A (en) * | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
WO1997043245A1 (en) * | 1996-05-15 | 1997-11-20 | Bayer Corporation | Inhibition of matrix metalloproteases by acetylene containing compounds |
WO1998016503A2 (en) * | 1996-10-16 | 1998-04-23 | American Cyanamid Company | The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
WO1999018076A1 (en) * | 1997-10-06 | 1999-04-15 | American Cyanamid Company | The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US5977408A (en) * | 1996-10-16 | 1999-11-02 | American Cyanamid Company | Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
-
2000
- 2000-01-26 AR ARP000100325A patent/AR035478A1/es not_active Application Discontinuation
- 2000-01-27 KR KR1020017009153A patent/KR20010089617A/ko not_active Application Discontinuation
- 2000-01-27 EA EA200100808A patent/EA200100808A1/ru unknown
- 2000-01-27 JP JP2000595968A patent/JP2002535383A/ja active Pending
- 2000-01-27 BR BR0007754-2A patent/BR0007754A/pt not_active IP Right Cessation
- 2000-01-27 NZ NZ512025A patent/NZ512025A/en unknown
- 2000-01-27 WO PCT/US2000/001865 patent/WO2000044711A1/en not_active Application Discontinuation
- 2000-01-27 IL IL14432100A patent/IL144321A0/xx unknown
- 2000-01-27 AU AU26306/00A patent/AU769410B2/en not_active Ceased
- 2000-01-27 CA CA002356345A patent/CA2356345A1/en not_active Abandoned
- 2000-01-27 CZ CZ20012709A patent/CZ20012709A3/cs unknown
- 2000-01-27 CN CN00803031A patent/CN1337944A/zh active Pending
- 2000-01-27 EP EP00904570A patent/EP1147078A1/en not_active Withdrawn
- 2000-01-27 HU HU0200605A patent/HUP0200605A3/hu unknown
-
2001
- 2001-05-31 ZA ZA200104508A patent/ZA200104508B/xx unknown
- 2001-07-24 NO NO20013639A patent/NO20013639D0/no not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514716A (en) * | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
WO1997043245A1 (en) * | 1996-05-15 | 1997-11-20 | Bayer Corporation | Inhibition of matrix metalloproteases by acetylene containing compounds |
WO1998016503A2 (en) * | 1996-10-16 | 1998-04-23 | American Cyanamid Company | The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US5977408A (en) * | 1996-10-16 | 1999-11-02 | American Cyanamid Company | Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
WO1999018076A1 (en) * | 1997-10-06 | 1999-04-15 | American Cyanamid Company | The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, vol. 89, no. 21, 20 November 1978, Columbus, Ohio, US; abstract no. 179808, ALLABERGENOV, K.D. ET AL.: "Corrosion inhibiting effect of acetylenic amino ethers of substituted phenols" * |
DATABASE REGISTRY CAS; XP002137201 * |
IZV. VYSSH. UCHEBN. ZAVED., KHIM. KHIM. TECHNOL., vol. 21, no. 4, 1978, pages 478 - 480 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
US7485667B2 (en) | 2002-12-23 | 2009-02-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
WO2005092844A1 (en) * | 2004-03-22 | 2005-10-06 | Southern Research Institute | Nonpeptide inhibitors of matrix metalloproteinases |
US8129406B2 (en) | 2004-03-22 | 2012-03-06 | Southern Research Institute | Nonpeptide inhibitors of matrix metalloproteinases |
AU2005227311B2 (en) * | 2004-03-22 | 2012-03-15 | Southern Research Institute | Nonpeptide inhibitors of matrix metalloproteinases |
US8633196B2 (en) | 2009-06-30 | 2014-01-21 | Galderma Research & Development | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
US8980897B2 (en) | 2009-06-30 | 2015-03-17 | Galderma Research & Development | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
US9365529B2 (en) | 2009-06-30 | 2016-06-14 | Galderma Research & Devlopment | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
US9115102B2 (en) | 2009-09-17 | 2015-08-25 | Galderma Research & Development | N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Also Published As
Publication number | Publication date |
---|---|
NZ512025A (en) | 2003-08-29 |
EP1147078A1 (en) | 2001-10-24 |
NO20013639L (no) | 2001-07-24 |
ZA200104508B (en) | 2002-09-02 |
CZ20012709A3 (cs) | 2002-04-17 |
HUP0200605A3 (en) | 2005-05-30 |
HUP0200605A2 (hu) | 2002-07-29 |
CA2356345A1 (en) | 2000-08-03 |
AR035478A1 (es) | 2004-06-02 |
NO20013639D0 (no) | 2001-07-24 |
AU769410B2 (en) | 2004-01-29 |
CN1337944A (zh) | 2002-02-27 |
EA200100808A1 (ru) | 2001-12-24 |
JP2002535383A (ja) | 2002-10-22 |
KR20010089617A (ko) | 2001-10-06 |
BR0007754A (pt) | 2001-11-13 |
AU2630600A (en) | 2000-08-18 |
IL144321A0 (en) | 2002-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6313123B1 (en) | Acetylenic sulfonamide thiol tace inhibitors | |
AU766192B2 (en) | Acetylenic sulfonamide thiol tace inhibitors | |
US6326516B1 (en) | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors | |
US6200996B1 (en) | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors | |
US6277885B1 (en) | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | |
EP1144369B1 (en) | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors | |
AU769410B2 (en) | Acetylenic beta-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors | |
US6762178B2 (en) | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | |
EP1147102B1 (en) | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors | |
US20020188132A1 (en) | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | |
MXPA01007465A (en) | ACETYLENIC&bgr;-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | |
US20040127524A1 (en) | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | |
MXPA01007470A (es) | Inhibidores de tace de aril-sulfonamida acetilenica y acido fosfinico-acido amido-hidroxamico | |
MXPA01007574A (en) | Acetylenic sulfonamide thiol tace inhibitors | |
MXPA01007513A (en) | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00803031.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 512025 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200104508 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 26306/00 Country of ref document: AU Ref document number: 2000904570 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2356345 Country of ref document: CA Ref document number: 2356345 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 144321 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017009153 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2000 595968 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/007465 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-2709 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200100808 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017009153 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000904570 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-2709 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 26306/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000904570 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017009153 Country of ref document: KR |